Rheumatologists living in Ukraine press on with their work of treating patients despite the ongoing war that began with a Russian military invasion.
Marching to the Biosimilar Beat: Questions on Rollout Remain
The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
How to Optimize Treatment for Aging Patients with Rheumatic Conditions
As patients with rheumatic musculoskeletal disease age, the number of medications they take may increase (i.e., polypharmacy), which can result in unwanted side effects and serious adverse effects. Lee et al. offer considerations and insights into caring for aging patients in a polypharmacy situation to better meet their health and lifestyle needs.
Drinking Raises Risk of Hip Replacement Due to OA
Marchand et al. sought to examine the relationship between alcohol consumption and hip osteoarthritis (OA) in women. By analyzing data from the Nurses’ Health Study cohort in the U.S., the researchers concluded that an association may be observed between higher alcohol consumption and greater incidence of total hip replacement due to OA.
In Memoriam: Rodanthi Kitridou, a Titan of Rheumatology
Dr. Rodanthi Kitridou is fondly remembered by a mentee as a trailblazer and role model.
In Memoriam: The Far-Reaching Legacy of Naomi Rothfield, MD, MACR
A tribute to the life and distinguished career of Naomi Rothfield, MD, MACR.
Fight for Change: 2 ARP Members on Why Advocacy Is Important to Them
Two ARP members who currently serve on the ACR Government Affairs Committee discuss why & how they got involved in advocacy.
ACR White Paper, Position Statement Address Rheumatology’s Benefits
A new white paper and position statement from the ACR address the clinical and economic value of rheumatology, including patient outcomes and healthcare cost savings.
2024 Proposed Rule for the Quality Payment Program Released
See key changes for the Merit-Based Incentive Payment System for the 2024 performance year as outlined in the proposed rule.
A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA
Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…
- « Previous Page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- …
- 814
- Next Page »